Detalhe da pesquisa
1.
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
N Engl J Med
; 389(26): 2436-2445, 2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921461
2.
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Lancet
; 401(10388): 1584-1594, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015244
3.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Lancet
; 402(10417): 2077-2090, 2023 12 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931634
4.
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Kidney Int Rep
; 9(4): 1020-1030, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38765567
5.
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Kidney Int Rep
; 8(5): 1043-1056, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37180506
6.
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis.
Kidney Int Rep
; 5(4): 494-502, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-32274453
7.
Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.
Cancer Res
; 63(11): 2997-3000, 2003 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12782609
8.
Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys.
Lancet
; 362(9400): 1953-8, 2003 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-14683653
9.
Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/factor VIIa complex, in patients undergoing elective coronary angioplasty.
J Am Coll Cardiol
; 41(12): 2147-53, 2003 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-12821239
10.
Inhibition of factor VIIa/tissue factor with nematode anticoagulant protein c2: from unique mechanism to a promising new clinical anticoagulant.
Trends Cardiovasc Med
; 12(8): 325-31, 2002 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-12536118
11.
Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X.
Thromb Haemost
; 90(5): 803-12, 2003 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-14597974
12.
Endotoxaemia induces resistance to activated protein C in healthy humans.
Br J Haematol
; 134(2): 213-9, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16846480
13.
Local activation of the tissue factor-factor VIIa pathway in patients with pneumonia and the effect of inhibition of this pathway in murine pneumococcal pneumonia.
Crit Care Med
; 34(6): 1725-30, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16625114
14.
Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects.
Clin Diagn Lab Immunol
; 10(3): 495-7, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12738659
15.
Inhibition of the tissue factor/factor VIIa pathway does not influence the inflammatory or antibacterial response to abdominal sepsis induced by Escherichia coli in mice.
J Infect Dis
; 189(12): 2308-17, 2004 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15181580